|
1
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bielack SS, Kempf-Bielack B, Delling G,
Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M,
Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma
of the extremities or trunk: An analysis of 1,702 patients treated
on neoadjuvant cooperative osteosarcoma study group protocols. J
Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hanif IM, Hanif IM, Shazib MA, Ahmad KA
and Pervaiz S: Casein Kinase II: An attractive target for
anti-cancer drug design. Int J Biochem Cell Biol. 42:1602–1605.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Meggio F and Pinna LA:
One-thousand-and-one substrates of protein kinase CK2? FASEB J.
17:349–368. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahmad KA, Harris NH, Johnson AD, Lindvall
HC, Wang G and Ahmed K: Protein kinase CK2 modulates apoptosis
induced by resveratrol and epigallocatechin-3-gallate in prostate
cancer cells. Mol Cancer Ther. 6:1006–1012. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Faust RA, Gapany M, Tristani P, Davis A,
Adams GL and Ahmed K: Elevated protein kinase CK2 activity in
chromatin of head and neck tumors: Association with malignant
transformation. Cancer Lett. 101:31–35. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim JS, Eom JI, Cheong JW, Choi AJ, Lee
JK, Yang WI and Min YH: Protein kinase CK2alpha as an unfavorable
prognostic marker and novel therapeutic target in acute myeloid
leukemia. Clin Cancer Res. 13:1019–1028. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Y, Amin EB, Mayo MW, Chudgar NP,
Bucciarelli PR, Kadota K, Adusumilli PS and Jones DR: CK2α drives
lung cancer metastasis by targeting BRMS1 nuclear export and
degradation. Cancer Res. 76:2675–2686. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siddiqui-Jain A, Drygin D, Streiner N,
Chua P, Pierre F, O'Brien SE, Bliesath J, Omori M, Huser N, Ho C,
et al: CX-4945, an orally bioavailable selective inhibitor of
protein kinase CK2, inhibits prosurvival and angiogenic signaling
and exhibits antitumor efficacy. Cancer Res. 70:10288–10298. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferguson AD, Sheth PR, Basso AD, Paliwal
S, Gray K, Fischmann TO and Le HV: Structural basis of CX-4945
binding to human protein kinase CK2. FEBS Lett. 585:104–110. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cozza G, Pinna LA and Moro S: Protein
kinase CK2 inhibitors: A patent review. Expert Opin Ther Pat.
22:1081–1097. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim J and Kim SH: Druggability of the CK2
inhibitor CX-4945 as an anticancer drug and beyond. Arch Pharm Res.
35:1293–1296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sarno S, Papinutto E, Franchin C, Bain J,
Elliott M, Meggio F, Kazimierczuk Z, Orzeszko A, Zanotti G,
Battistutta R, et al: ATP site-directed inhibitors of protein
kinase CK2: An update. Curr Top Med Chem. 11:1340–1351. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bettendorff L, Wirtzfeld B, Makarchikov
AF, Mazzucchelli G, Frédérich M, Gigliobianco T, Gangolf M, De Pauw
E, Angenot L and Wins P: Discovery of a natural thiamine adenine
nucleotide. Nat Chem Biol. 3:211–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pizzi M, Piazza F, Agostinelli C, Fuligni
F, Benvenuti P, Mandato E, Casellato A, Rugge M, Semenzato G and
Pileri SA: Protein kinase CK2 is widely expressed in follicular,
Burkitt and diffuse large B-cell lymphomas and propels malignant
B-cell growth. Oncotarget. 6:6544–6552. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nakamura S, Nagano S, Nagao H, Ishidou Y,
Yokouchi M, Abematsu M, Yamamoto T, Komiya S and Setoguchi T:
Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI
transcription via DNA damage accumulation. PLoS One. 8:e694662013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagao H, Ijiri K, Hirotsu M, Ishidou Y,
Yamamoto T, Nagano S, Takizawa T, Nakashima K, Komiya S and
Setoguchi T: Role of GLI2 in the growth of human osteosarcoma. J
Pathol. 224:169–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kulbe H, Iorio F, Chakravarty P, Milagre
CS, Moore R, Thompson RG, Everitt G, Canosa M, Montoya A, Drygin D,
et al: Integrated transcriptomic and proteomic analysis identifies
protein kinase CK2 as a key signaling node in an inflammatory
cytokine network in ovarian cancer cells. Oncotarget.
7:15648–15661. 2016.PubMed/NCBI
|
|
20
|
Son YH, Song JS, Kim SH and Kim J:
Pharmacokinetic characterization of CK2 inhibitor CX-4945. Arch
Pharm Res. 36:840–845. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Son YH, Moon SH and Kim J: The protein
kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast
differentiation in vitro. Mol Cells. 36:417–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trembley JH, Unger GM, Korman VL, Abedin
MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT and Ahmed K: Tenfibgen
ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi
oligomer to key sites for prostate cancer targeting using human
xenograft tumors in mice. PLoS One. 9:e1099702014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Unger GM, Kren BT, Korman VL, Kimbrough
TG, Vogel RI, Ondrey FG, Trembley JH and Ahmed K: Mechanism and
efficacy of sub-50-nm tenfibgen nanocapsules for cancer
cell-directed delivery of anti-CK2 RNAi to primary and metastatic
squamous cell carcinoma. Mol Cancer Ther. 13:2018–2029. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Giusiano S, Cochet C, Filhol O,
Duchemin-Pelletier E, Secq V, Bonnier P, Carcopino X, Boubli L,
Birnbaum D, Garcia S, et al: Protein kinase CK2α subunit
over-expression correlates with metastatic risk in breast
carcinomas: Quantitative immunohistochemistry in tissue
microarrays. Eur J Cancer. 47:792–801. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gapany M, Faust RA, Tawfic S, Davis A,
Adams GL and Ahmed K: Association of elevated protein kinase CK2
activity with aggressive behavior of squamous cell carcinoma of the
head and neck. Mol Med. 1:659–666. 1995.PubMed/NCBI
|
|
26
|
Yang W, Liu X, Choy E, Mankin H, Hornicek
FJ and Duan Z: Targeting hedgehog-GLI-2 pathway in osteosarcoma. J
Orthop Res. 31:502–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saitoh Y, Setoguchi T, Nagata M, Tsuru A,
Nakamura S, Nagano S, Ishidou Y, Nagao-Kitamoto H, Yokouchi M,
Maeda S, et al: Combination of Hedgehog inhibitors and standard
anticancer agents synergistically prevent osteosarcoma growth. Int
J Oncol. 48:235–242. 2016.PubMed/NCBI
|
|
28
|
Nagao-Kitamoto H, Setoguchi T, Kitamoto S,
Nakamura S, Tsuru A, Nagata M, Nagano S, Ishidou Y, Yokouchi M,
Kitajima S, et al: Ribosomal protein S3 regulates GLI2-mediated
osteosarcoma invasion. Cancer Lett 356B. 855–861. 2015. View Article : Google Scholar
|
|
29
|
Nagao-Kitamoto H, Nagata M, Nagano S,
Kitamoto S, Ishidou Y, Yamamoto T, Nakamura S, Tsuru A, Abematsu M,
Fujimoto Y, et al: GLI2 is a novel therapeutic target for
metastasis of osteosarcoma. Int J Cancer. 136:1276–1284. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hirotsu M, Setoguchi T, Sasaki H,
Matsunoshita Y, Gao H, Nagao H, Kunigou O and Komiya S: Smoothened
as a new therapeutic target for human osteosarcoma. Mol Cancer.
9:52010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang S, Yang YL, Wang Y, You B, Dai Y,
Chan G, Hsieh D, Kim IJ, Fang LT, Au A, et al: CK2α, over-expressed
in human malignant pleural mesothelioma, regulates the Hedgehog
signaling pathway in mesothelioma cells. J Exp Clin Cancer Res.
33:932014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang AQ, Cao XC, Tian L, He L and Liu F:
Apigenin inhibits the self-renewal capacity of human ovarian cancer
SKOV3-derived sphere-forming cells. Mol Med Rep. 11:2221–2226.
2015.PubMed/NCBI
|
|
33
|
Wu D, Sui C, Meng F, Tian X, Fu L, Li Y,
Qi X, Cui H, Liu Y and Jiang Y: Stable knockdown of protein kinase
CK2-alpha (CK2α) inhibits migration and invasion and induces
inactivation of hedgehog signaling pathway in hepatocellular
carcinoma Hep G2 cells. Acta Histochem. 116:1501–1508. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ,
Hu LM, Xu Z, Long H, Jablons DM and You L: Inhibition of CK2α
down-regulates Hedgehog/Gli signaling leading to a reduction of a
stem-like side population in human lung cancer cells. PLoS One.
7:e389962012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin Z, Mei W, Strack S, Jia J and Yang J:
The antagonistic action of B56-containing protein phosphatase 2As
and casein kinase 2 controls the phosphorylation and Gli turnover
function of Daz interacting protein 1. J Biol Chem.
286:36171–36179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jia H, Liu Y, Xia R, Tong C, Yue T, Jiang
J and Jia J: Casein kinase 2 promotes Hedgehog signaling by
regulating both smoothened and Cubitus interruptus. J Biol Chem.
285:37218–37226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim J, Choi WJ, Moon SH, Jung J, Park JK,
Kim SH and Lee JO: Micropillar arrays as potential drug screens:
Inhibition of micropillar-mediated activation of the
FAK-Src-paxillin signaling pathway by the CK2 inhibitor CX-4945.
Acta Biomater. 27:13–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bian Y, Han J, Kannabiran V, Mohan S,
Cheng H, Friedman J, Zhang L, VanWaes C and Chen Z: MEK inhibitor
PD-0325901 overcomes resistance to CK2 inhibitor CX-4945 and
exhibits anti-tumor activity in head and neck cancer. Int J Biol
Sci. 11:411–422. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Intemann J, Saidu NE, Schwind L and
Montenarh M: ER stress signaling in ARPE-19 cells after inhibition
of protein kinase CK2 by CX-4945. Cell Signal. 26:1567–1575. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang S, Long H, Yang YL, Wang Y, Hsieh D,
Li W, Au A, Stoppler HJ, Xu Z, Jablons DM, et al: Inhibition of
CK2α down-regulates Notch1 signalling in lung cancer cells. J Cell
Mol Med. 17:854–862. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bliesath J, Huser N, Omori M, Bunag D,
Proffitt C, Streiner N, Ho C, Siddiqui-Jain A, O'Brien SE, Lim JK,
et al: Combined inhibition of EGFR and CK2 augments the attenuation
of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer
Lett. 322:113–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Martins LR, Lúcio P, Melão A, Antunes I,
Cardoso BA, Stansfield R, Bertilaccio MT, Ghia P, Drygin D, Silva
MG, et al: Activity of the clinical-stage CK2-specific inhibitor
CX-4945 against chronic lymphocytic leukemia. Leukemia. 28:179–182.
2014. View Article : Google Scholar : PubMed/NCBI
|
